Should you buy or sell zomedica (Zom) stock?
Should you buy or sell Zomedica (ZOM) stock? Penny stocks require extra caution, and Zomedica stock is no exception. But ZOM looks like it could pay off well for patient investors—at about 80 percent below its peak, it could be a good deal.
When is zomedica's next quarterly earnings release?
Zomedica is scheduled to release its next quarterly earnings announcement on Thursday, February 24th 2022. View our earnings forecast for Zomedica. How were Zomedica's earnings last quarter?
Will zomedica stock outperform or underperform the S&P 500 over the long term?
Vote “Outperform” if you believe ZOM will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ZOM will underperform the S&P 500 over the long term. You may vote once every thirty days. Zomedica does not currently pay a dividend. Zomedica does not have a long track record of dividend growth.
What is the ticker symbol for zomedica?
Zomedica trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "ZOM." Who are Zomedica's major shareholders? Zomedica's stock is owned by a number of retail and institutional investors.
Is Zomedica expected to rise?
Zomedica Stock Price Forecast 2022-2023 The forecasted Zomedica price at the end of 2022 is $0.39 - and the year to year change +27%. The rise from today to year-end: +50%. In the middle of 2022, we expect to see $0.30 per 1 Zomedica.
Is Zomedica stock a good buy?
In the final analysis, ZOM stock is highly risky and best suited for speculative traders. Yet it's possible that retail traders will bid the stock up in 2022. And if they abandon Zomedica, it would be a dog-gone shame.
Is Zomedica being shorted?
Zomedica saw a increase in short interest during the month of May. As of May 31st, there was short interest totaling 116,080,000 shares, an increase of 3.1% from the previous total of 112,640,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment.
Why is Zomedica stock dropping?
The reason behind the decline goes back into the previous week, when Zomedica announced its third-quarter results after the market close on Nov. 12. The veterinary health company reported revenue in the third quarter of only $22,514. It posted a net loss of $6.3 million, or $0.091 per share.
Will Zomedica be delisted?
(NYSE American: ZOM) (TSX-V: ZOM) (“Zomedica” or the “Company”) a veterinary diagnostic and pharmaceutical company, today announced that it has received approval of its application to delist its common shares from the TSX Venture Exchange (“TSXV”) effective at the close of business on February 10, 2020.
What does Zomedica do?
Zomedica Corp. operates as a veterinary health company, which engages in the discovery, development, and commercialization of pharmaceuticals for the companion pet. It offers products for dogs and cats by focusing on the unmet needs of clinical veterinarians.
Who is shorting AMC?
Group One Trading LP. Wolverine Trading LLC. Bank of America Corp DE. Millennium Management LLC.
What is Fintel io?
About Fintel.io: Fintel.io is a leading equity research platform designed to help data-driven investors make better investing decisions. Fintel provides deep an. Fintel currently tracks over 30,000 funds and over 63,000 securities traded worldwide.
Is Zomedica a pump and dump?
Zomedica Pharmaceuticals (NYSEMKT:ZOM) stock is the latest pump-and-dump looking to take investors for a ride.
What is the target price for ZOM stock?
Stock Price TargetsHigh$1.20Median$1.20Low$1.20Average$1.20Current Price$0.26
Does ZOM reverse split?
Despite now generating revenue from the sale of its Truforma diagnostics system, Zomedica is valued at nearly 70 times Wall Street's projected sales for 2023. It's also nowhere near profitability. It's a strong candidate to enact a reverse split sometime over the next 12 to 18 months.
What is Zomedica product?
Based in Ann Arbor, Michigan, Zomedica (NYSE American:ZOM) is a veterinary health company creating products for companion animals by focusing on the unmet needs of clinical veterinarians.
Will NAKD stock go up?
Unfortunately, there are several loopholes in its turnaround strategy, so it is unlikely things will change significantly for the company. The pandemic-led tailwinds are fading quickly and will impact growth in its online business. Hence, NAKD stock is an unappealing investment with a murky outlook.
Is Zom a buy Zacks?
See rankings and related performance below. The VGM Score are a complementary set of indicators to use alongside the Zacks Rank....Momentum Scorecard. More Info.Zacks RankDefinitionAnnualized Return1Strong Buy25.08%2Buy18.56%3Hold10.15%4Sell5.79%2 more rows
Is Castor Maritime a good stock to buy?
If you are looking for stocks with good return, Castor Maritime Inc can be a profitable investment option. Castor Maritime Inc quote is equal to 1.455 USD at 2022-06-17. Based on our forecasts, a long-term increase is expected, the "CTRM" stock price prognosis for 2027-06-11 is 2.114 USD.
Signals & Forecast
The Zomedica Pharmaceuticals Corp stock holds buy signals from both short and long-term moving averages giving a positive forecast for the stock. Also, there is a general buy signal from the relation between the two signals where the short-term average is above the long-term average.
Support, Risk & Stop-loss
Zomedica Pharmaceuticals Corp finds support from accumulated volume at $0.36 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.
Is Zomedica Pharmaceuticals Corp stock A Buy?
Zomedica Pharmaceuticals Corp holds several positive signals, but we still don't find these to be enough for a buy candidate. At the current level, it should be considered as a hold candidate (hold or accumulate) in this position whilst awaiting further development.
Insiders are very positive buying more shares than they are selling in Zomedica Pharmaceuticals Corp
In the last 100 trades there were 77.16 million shares bought and 11.3 million shares sold. The last trade was done 97 days ago by Powers Johnny D who bough 250 thousand shares. The large amount of stocks bought compared to stocks sold indicate that the insiders believe there is a potential good upside.
Golden Star Signal
This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star. This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!
Top Fintech Company
featured in The Global Fintech Index 2020 as the top Fintech company of the country.
How much money did Zom make from stock sale?
ZOM has generated roughly $200 million in proceeds from the stock sale and intends to use it for the continued development of its diagnostic platforms, strategic acquisitions and for other general corporate and working capital purposes.
How much did Zom make in 2020?
ZOM also generated roughly $30 million last July 2020 through a public offering of its common shares.
Is Zom a pharmaceutical company?
ZOM operates in a small niche in the pharmaceutical space, focused solely on developing products for companion animals. So, a lot is riding on the company’s commercialization of its Truforma diagnostic product. However, ZOM has so far failed to impress investors and the stock plunged sharply after its first sale.
Earnings Recap
Zomedica recorded a third-quarter 2021 net loss of $6.3 million, or $0.01 per share, up from a loss of $5 million, or $0.01 per share reported in the same quarter last year. Notably, lower research and development (R&D) costs were offset by a rise in selling, general and administrative (SG&A) expenses.
Risk Analysis
According to the new TipRanks’ Risk Factors tool, Zomedica stock is at risk mainly from three factors: Finance and Corporate, Production, and Ability to Sell, which contribute 48%, 15%, and 11%, respectively, to the total 62 risks identified for the stock.
Latest Stocks Videos
In The Money: Groundhog Day: Mega-Cap Tech Stocks Out From the Shadows? Feb 02, 2022
TipRanks
TipRanks is the most comprehensive data set of sell side analysts and hedge fund managers. TipRanks' multi-award winning platform ranks financial experts based on measured performance and the accuracy of their predictions so investors know who to trust when making investment decisions.
Patiently Waiting
Anyone else still waiting on their 2020 tax return to make their next big ZOM purchase. I know I am 🥴🥴🥴
Anyone one else share my pain? Still hopeful this will pay off in the future though
A subreddit for discussing all things $ZOM. Please read the rules before posting and commenting.
About Zomedica
Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company engages in the development and commercialization of TRUFORMA, a diagnostic biosensor platform for the detection of thyroid disorders in dogs and cats, and adrenal disorders in dogs.
Zomedica (NYSEAMERICAN:ZOM) Frequently Asked Questions
Zomedica's stock was trading at $0.2078 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, ZOM stock has increased by 63.8% and is now trading at $0.3403. View which stocks have been most impacted by COVID-19.
What is Zomedica Pharmaceuticals?
Zomedica Corp. is a veterinary health company. It creates products for companion animals by focusing on the unmet needs of clinical veterinarians. Zomedica Corp., formerly known as Zomedica Pharmaceuticals Corp., is based in Ann Arbor, Michigan.
What is a strong weekly advance?
A strong weekly advance (especially when accompanied by increased volume) is a sought after metric for putting potential momentum stocks onto one's radar. Others will look for a pullback on the week as a good entry point, assuming the longer-term price changes (4 week, 12 weeks, etc.) are strong.